Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing
- PMID: 26451311
- PMCID: PMC4589054
- DOI: 10.1080/2162402X.2015.1030561
Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing
Abstract
Tumor-infiltrating lymphocytes (TILs) play an important role in regulating the host immune response and are one of key factors in defining tumor microenvironment. Some studies have indicated that T cell infiltration in malignant ascites is associated with clinical outcome, but few studies have performed detailed characterization of T cell diversity or clonality in malignant effusions. We have applied a next generation sequencing method to characterize T cell repertoire of a set of primary cancers, ascites, and blood from 12 ovarian cancer patients and also analyzed the T cell subtype populations in malignant fluids from 3 ovarian cancer patients. We observed enrichment of certain T cells in tumors and ascites, but most of the enriched T cell receptor (TCR) sequences in tumors and ascites were not common. Moreover, we analyzed TCR sequences of T cell subtypes (CD4+, CD8+, and regulatory T cells) isolated from malignant effusions and also found clonal expansion of certain T cell populations, but the TCR sequences were almost mutually exclusive among the three subgroups. Although functional studies of clonally expanded T cell populations are definitely required, our approach offers a detailed characterization of T cell immune microenvironment in tumors and ascites that might differently affect antitumor immune response.
Keywords: T cell receptor; malignant ascites; next generation sequencing; ovarian cancer; tumor immunity.
Figures






Similar articles
-
Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer.PLoS One. 2023 Jan 6;18(1):e0279590. doi: 10.1371/journal.pone.0279590. eCollection 2023. PLoS One. 2023. PMID: 36607962 Free PMC article.
-
Characterization of ascites- and tumor-infiltrating γδ T cells reveals distinct repertoires and a beneficial role in ovarian cancer.Sci Transl Med. 2021 Jan 20;13(577):eabb0192. doi: 10.1126/scitranslmed.abb0192. Sci Transl Med. 2021. PMID: 33472952
-
Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer.Oncotarget. 2020 Jul 7;11(27):2669-2683. doi: 10.18632/oncotarget.27666. eCollection 2020 Jul 7. Oncotarget. 2020. PMID: 32676168 Free PMC article.
-
The Emerging Role of CD8+ Tissue Resident Memory T (TRM) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin.Front Immunol. 2018 Aug 15;9:1904. doi: 10.3389/fimmu.2018.01904. eCollection 2018. Front Immunol. 2018. PMID: 30158938 Free PMC article. Review.
-
Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.Breast Cancer. 2017 Jan;24(1):3-15. doi: 10.1007/s12282-016-0698-z. Epub 2016 May 2. Breast Cancer. 2017. PMID: 27138387 Review.
Cited by
-
The era of immunogenomics/immunopharmacogenomics.J Hum Genet. 2018 Jul;63(8):865-875. doi: 10.1038/s10038-018-0468-1. Epub 2018 May 21. J Hum Genet. 2018. PMID: 29785006 Review.
-
Immune Tumor Microenvironment in Ovarian Cancer Ascites.Int J Mol Sci. 2022 Sep 14;23(18):10692. doi: 10.3390/ijms231810692. Int J Mol Sci. 2022. PMID: 36142615 Free PMC article. Review.
-
Characterization of the cryoablation-induced immune response in kidney cancer patients.Oncoimmunology. 2017 May 16;6(7):e1326441. doi: 10.1080/2162402X.2017.1326441. eCollection 2017. Oncoimmunology. 2017. PMID: 28811963 Free PMC article.
-
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia.Exp Hematol Oncol. 2022 Nov 16;11(1):100. doi: 10.1186/s40164-022-00353-3. Exp Hematol Oncol. 2022. PMID: 36384590 Free PMC article. Review.
-
Biophysicochemical motifs in T cell receptor sequences as a potential biomarker for high-grade serous ovarian carcinoma.PLoS One. 2020 Mar 5;15(3):e0229569. doi: 10.1371/journal.pone.0229569. eCollection 2020. PLoS One. 2020. PMID: 32134923 Free PMC article.
References
-
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208 - DOI - PubMed
-
- Ayhan A, Gultekin M, Taskiran C, Dursun P, Firat P, Bozdag G, Celik NY, Yuce K. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer 2007; 17:68-75; PMID:17291234; http://dx.doi.org/10.1111/j.1525-1438.2006.00777.x - DOI - PubMed
-
- Parsons SL, Lang MW, Steele RJ. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol 1996; 22:237-9; PMID:8654603; http://dx.doi.org/10.1016/S0748-7983(96)80009-6 - DOI - PubMed
-
- Sheid B. Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer. Cancer Lett 1992; 62:153-8; PMID:1371714; http://dx.doi.org/10.1016/0304-3835(92)90186-Y - DOI - PubMed
-
- Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, Freedman RS. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 1991; 51:4257-65; PMID:1868446 - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials